listed as recruiting on clinicaltrials.gov: ODYSSEY Mono (alirocumab compared with ezetimibe in patients with hypercholesterolemia), ODYSSEY Combo I and II (evaluates alirocumab in combination with lipid modifying therapy in patients with hypercholesterolemia at high cardiovascular risk), ODYSSEY High FH (evaluates alirocumab in combination with lipid modifying therapy in patients with familial hypercholesterolemia), ODYSSEY FHI (evaluates alirocumab in patients with familial hypercholesterolemia that is not adequately controlled), ODYSSEY Alternative (evaluates alirocumab in patients with hypercholesterolemia and cardiovascular risk who are intolerant to statins), ODYSSEY Outcomes (compares the effect of alirocumab with placebo on the occurrence of cardiovascular events in patients who have experienced an acute coronary syndrome event), and ODYSSEY Long-term (evaluated the long-term safety and tolerability of alirocumab in patients with hypercholesterolemia and cardiovascular risk). The completion dates for these studies are between November 2013 (ODYSSEY Mono) and March 2018 (ODYSSEY Outcomes).
Two anti-IL-5 mAbs, IgG1 mepolizumab and IgG4 reslizumab, are in multiple Phase 3 studies that are actively recruiting patients. Mepolizumab is currently undergoing evaluation in six Phase 3 studies; patients with asthma are being recruited for four studies, while patients with hypereosinophilic syndrome and patients with chronic obstructive pulmonary diseases and eosinophilic bronchitis are each being recruited for one study. The completion dates for these six studies range from March 2013 to December 2016. Patients are currently being recruited for a total of four Phase 3 studies of the safety and efficacy of reslizumab as a treatment for eosinophilic asthma. These four studies have estimated completion dates between June 2013 and January 2015.
IL-17a is the target of IgG4 ixekizumab and IgG1 secukinumab. Ixekizumab is undergoing evaluation as a treatment for moderate to severe psoriasis in three Phase 3 studies, UNCOVER-1, -2 and -3. These three studies have estimated completion dates between February 2018 and April 2019. Japanese patients with moderate to severe psoriasis are being recruited for an additional Phase 3 study of ixekizumab. A Phase 3 study of patients with active psoriatic arthritis was planned but had not yet started recruiting patients as of midNovember 2012. The safety and efficacy the start of the new year signals that it is time for mAbs' annual review of the therapeutic monoclonal antibodies (mAbs) in active Phase 2/3 or Phase 3 clinical studies. the entire clinical pipeline currently includes ~350 mAbs, but most of these are in early development. As of the beginning of 2013, our "Antibodies to watch" list includes 28 single mAbs and one mAb mixture that are undergoing evaluation in Phase 3 studies for inflammatory or immunological disorders, cancers, high cholesterol, osteoporosis, Alzheimer disease and infectious disease. in alphabetical order, the 28 mabs are alirocumab, AMG 145, elotuzumab, epratuzumab, farletuzumab, gantenerumab, gevokizumab, inotuzumab ozogamicin, itolizumab, ixekizumab, lebrikizumab, mepolizumab, naptumomab estafenatox, necitumumab, nivolumab, obinutuzumab, ocrelizumab, onartuzumab, racotumomab, ramucirumab, reslizumab, romosozumab, sarilumab, secukinumab, sirukumab, solanezumab, tabalumab and vedolizumab. the mixture of actoxumab and bezlotoxumab is being evaluated in two Phase 3 studies as a treatment for Clostridium difficile infection.
indicated the overall benefit to risk profile of ocrelizumab was not favorable in RA.
Ten of the antibodies to watch in 2013 are undergoing evaluation as cancer treatments ( Table 2) . Seven of the ten are fulllength, unmodified mAbs; inotuzumab ozogamicin is an antibody-drug conjugate (ADC), onartuzumab comprises a Fab-Fc fusion and naptumomab estafenatox is a Fab-based immunotoxin. Naptumomab estafenatox combined with interferon (IFN)-α vs. IFN-α alone in renal cell carcinoma patients was evaluated in a Phase 2/3 study (NCT00420888). Active Biotech has indicated that they expect results of the study results to be presented in the first quarter of 2013. Several Phase 3 studies of ramucirumab are due for completion in a treatment for RA. The RA-MOBILITY study (NCT01061736), which is evaluating the effects of sarilumab on top of methotrexate in RA patients, is due for completion in October 2013. A Phase 3 study started in June 2010 that evaluated the long-term safety and efficacy of sarilumab in ankylosing spondylitis patients was terminated due to lack of benefit on efficacy. Ocrelizumab, an anti-CD20 humanized IgG1, is currently in two Phase 3 studies of patients with relapsing multiple sclerosis that have estimated completion dates in June and August of 2015. The Phase 3 FEATURE study of ocrelizumab in RA patients was terminated based on analysis of results and consideration of available treatments that of secukinumab are being evaluated in a total of 12 Phase 3 studies listed on clinicaltrials.gov as recruiting or active but not recruiting. Seven of the 12 studies include patients with psoriasis; study completion dates range from March 2013 to May 2015. Three Phase 3 studies of secukinumab in rheumatoid arthritis (RA) patients are due for completion between August 2013 and September 2018. Two additional Phase 3 studies, one each of patients with psoriatic arthritis or ankylosing spondylitis, have estimated completion dates in July 2014.
Several of the antibodies to watch in 2013 have had setbacks in development, e.g., sarilumab, ocrelizumab. Sarilumab, a human IgG1 that targets the IL-6 receptor is currently in two Phase 3 studies as 2013. A Phase 3 study (NCT00917384) of ramucirumab in patients with metastatic gastric or gastresophageal junction adenocarcinoma following disease progression on first-line platinum-or fluoropyrimidinecontaining combination therapy and the Phase 3 REACH study (NCT01140347) of ramucirumab as second-line treatment in hepatocellular carcinoma patients following first-line therapy with sorafenib have estimated completion dates in January and August 2013, respectively. Ramucirumab is also in Phase 3 studies as a treatment for breast, colorectal and non-small cell lung cancers. Phase 3 study results of farletuzumab in ovarian cancer may be released in 2013. In March 2012, Morphotek announced that a Phase 3 study (NCT00849667) of farletuzumab in combination with carboplatin and taxane in patients with platinumsensitive ovarian cancer in first relapse had reached its randomization target of 1080 patients; the final data collection date for primary outcome measures was estimated as September 2012. A previous Phase 3 study (NCT00738699) of farletuzumab in combination with paclitaxel therapy in patients with platinum-resistant or refractory relapsed ovarian cancer did not meet pre-specified criteria for continuation following interim futility analysis and was terminated. The Phase 3 SQUIRE study (NCT00981058) of gemcitabine-cisplatin chemotherapy plus necitumumab vs. gemcitabine-cisplatin chemotherapy alone in the first-line treatment of patients with Stage IV squamous non-small cell lung cancer has an estimated primary completion date of September 2013. Enrollment of the Phase 3 INSPIRE study (NCT00982111) of pemetrexed-cisplatin chemotherapy with necitumumab compared with the chemotherapy alone in the first-line treatment of patients with Stage IV nonsquamous non-small cell lung cancer was stopped because of safety concerns related to thromboembolism in the experimental study arm. Two Phase 2 studies of necitumumab as a treatment for solid tumors have estimated completion dates in July 2013.
mAbs looks forward to tracking the clinical study results that may be released during the year, but we also anticipate the first marketing approval of at least one therapeutic antibody in 2013. Trastuzumab emtansine, which is composed of trastuzumab (Herceptin ® ) conjugated to a cytotoxic drug, was given a 'priority review' designation by the US Food and Drug Administration; a decision on the marketing application is expected by February 26, 2013. The ADC is also undergoing regulatory review by the European Medicines Agency. Results of a Phase 2 study of trastuzumab emtansine as first-line treatment in previously untreated patients with HER2-positive metastatic breast cancer indicated that the ADC provided significant improvement in progression-free survival compared with the control treatment (trastuzumab plus docetaxel) and had a favorable safety profile. 5 
